Physician profile
Roy W Deen
NPI 1437263340
$2,813.85
in general payments reported to CMS, 2019-2025
32 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $375 · 2021: $609 · 2022: $382 · 2023: $365 · 2024: $473 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $394.62 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.71 | 2020-2025 | Xifaxan, Trulance |
| Amgen INC. | $197.66 | 2020-2024 | Krystexxa |
| Novo Nordisk INC | $182.59 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $175.13 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $174.24 | 2021-2025 | Vraylar |
| Pfizer INC. | $154.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $145.10 | 2019-2021 | |
| Lilly USA, LLC | $139.92 | 2020-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $119.05 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $98.21 | 2021 | |
| Exact Sciences Corporation | $98.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $89.82 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.46 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $83.67 | 2022-2024 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $71.94 | 2022 | |
| Allergan, INC. | $48.76 | 2019-2020 | |
| Corcept Therapeutics | $47.78 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $43.24 | 2021-2023 | Rexulti |
| Dexcom, INC. | $34.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $25.18 | 2022 | |
| Seqirus USA INC | $22.60 | 2025 | Flucelvax, Fluad |
| Biogen, INC. | $21.05 | 2020 | |
| Amarin Pharma, INC. | $20.91 | 2019 | |
| Medline Industries LP | $20.56 | 2024 | |
| Eisai INC. | $14.76 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.15 | 2023 | Pyrukynd |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2023 | Seglentis, Livalo |
| Mylan Specialty L.P. | $13.66 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.07 | 2020 | |
| Medtronic USA, INC. | $12.43 | 2020 | |
| Medtronic Vascular, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Deen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.